- Post‑transplant cyclophosphamide plus anti‑thymocyte globulin decreased serum IL‑6 levels when compared with post‑transplant cyclophosphamide alone after haploidentical hematopoietic stem cell transplantation
-
Koh J, Lee M, Pham T, Heo B, Choi S, Lee S, Seo W, Kang S, Lee S, Kim C, Ryu H, Eun H, Lee H, Yun H, Jo D, Song I
- KMID: 2563979
- Blood Res.
- 2025;60:5.
- doi: 10.1007/s44313-024-00049-z
Background Post-transplantation cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) are common pro‑ phylactic strategies for graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Interleukin (IL)-6 is a surrogate marker for cytokine release syndrome (CRS) and acute... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of bortezomib combined with Hyper‑CVAD in adults with relapsed acute lymphoblastic leukemia or positive measurable residual disease; effect of bortezomib in leukemia
-
Peñafiel C, Sámano D, Rodríguez A, Palacio C, Carrillo I, Murillo C, Lampón G, García , Tovar A
- KMID: 2563980
- Blood Res.
- 2025;60:4.
- doi: 10.1007/s44313-024-00050-6
Purpose Despite advances in the treatment of adult acute lymphoblastic leukemia (ALL), relapse remains the most significant challenge in improving prognosis. Measurable residual disease (MRD) assessment can predict bone marrow relapse based on MRD positivity. As... -
- CITED
-
- Close
- SHARE
-
- Close
- Pseudo Chediak‑Higashi anomaly in a diffuse large B‑cell lymphoma with hemophagocytic lymphohistiocytosis
-
Yi B, Zeng M
- KMID: 2563981
- Blood Res.
- 2025;60:2.
- doi: 10.1007/s44313-024-00052-4
-
- CITED
-
- Close
- SHARE
-
- Close
- Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta‑analysis according to 17p deletion/TP53 mutations
-
Kim J, Cho J, Lim J, Lee M
- KMID: 2563978
- Blood Res.
- 2025;60:1.
- doi: 10.1007/s44313-024-00038-2
Purpose This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically the 17p deletion and TP53 mutations. Methods We conducted a systematic literature... -
- CITED
-
- Close
- SHARE
-
- Close
